You're viewing the US edition You can switch to the UK, AU or IE homepage at any time using this menu. The face of France's far-Left madness: Pro-Palestine'feminist' tells woman who was threatened with rape during French protests that she is'collateral damage' 'Floating gold' worth thousands is being found washed up on America's beaches. Here's what to look out for... but beware its disgusting origins As Thomas Markle's son makes disturbing allegations against his father, the twisted feud raging in Meghan's family just took a sinister turn Met police say they DID receive letter about Thomas Markle in 2019 - as force'reviews its handling of the matter' Why did Meghan tell Netflix: 'I've been a Daddy's Girl my whole life' four years after Met received a letter making such disturbing allegations? Damning video reveals vulgar rant of MAGA star Joe Mitchell, then-19, about'black women' and not liking'f***ing white people' while boasting about his own manhood School bus carrying Georgia high school football team overturns on busy highway in terrifying crash... as nearby hospitals brace for potential'mass casualty event' I took the new lymphoedema drug and my leg swelling went down by a third. After years of wearing compression stockings, this daily pill finally worked.

The vaccine is personalized to a patient's tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer. The new mRNA vaccine is waiting on FDA approval but has shown great promise in Phase 3 clinical trials. An experimental vaccine offers new hope to patients with melanoma, one of the most aggressive forms of skin cancer . The pharmaceutical companies Merck and Moderna released the results of a Phase 3 clinical trial that evaluated the efficacy of a personalized mRNA-based vaccine that, when combined with immunotherapy, reduced the risk of disease recurrence or death by 42 percent compared to treatment with the immunotherapy drug alone. Georgina Long, medical director of the Australian Melanoma Institute and the study's principal investigator, said in a statement that these results are "transformative" and "have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma."

The company plans to offer testosterone replacement therapy, marking its first foray into prescribing controlled substances. Talk of testosterone deficiency is hard to escape these days, with podcasters and politicians obsessing over how to avoid a "low T" lifestyle. As the hormone's cultural salience deepens, demand is growing. In a timely move, telehealth giant Hims just launched a testosterone replacement therapy service for cisgender men. The direct-to-consumer juggernaut will offer two types of injectable treatments, as well as an oral pill option that can be sent to patients after they take an at-home capillary blood test.

Things to Do in L.A. Tap to enable a layout that focuses on the article. This is read by an automated voice. Please report any issues or inconsistencies here . See more from the L.A. Times in Google Search. At least nine California lawmakers, including Sen. Alex Padilla, are among dozens of officials and state election offices nationwide sent suspicious white-powder letters weeks before the Nov. 3 election.

After four weeks of using the cream, participants lowered the biological age of their skin by about two years on average. A wave of biotech companies is looking to prove that it's possible to slow down the aging process. Mountain View, California-based Rubedo Life Sciences is starting with the most outwardly visible sign: the skin. The company's experimental treatment is showing early promise that it may be able to reduce the appearance of aging, according to data the company presented at the Aging Research and Drug Discovery meeting in Boston earlier this month. In a small clinical trial, Rubedo tested its topical cream on 11 people with atopic dermatitis, an inflammatory skin condition and the most common type of eczema.

WIRED tested samples of four types of peptides. The results show how lightly regulated the industry is, even as popularity surges. The Mr. Green bodega sits on a busy stretch of Bedford Avenue in Brooklyn, New York. Near the counter, you can buy the usual assortment of candy, gum, rolling papers, and soda. You can also purchase tiny vials of injectable peptides .

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

The FDA could decide whether to loosen rules around peptide production this week. Some telehealth players are already seeing dollar signs. Has anyone tried to sell you peptides yet? Once a niche interest among bodybuilders and biohackers, peptides are an increasingly popular class of substance hyped by both fringe influencers and the current US Secretary of Health and Human Services. Earlier this year, Robert F. Kennedy Jr. told the podcaster Joe Rogan that the government intended to loosen restrictions on peptide production.